467 related articles for article (PubMed ID: 17616532)
1. Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells.
Suzuki-Inoue K; Kato Y; Inoue O; Kaneko MK; Mishima K; Yatomi Y; Yamazaki Y; Narimatsu H; Ozaki Y
J Biol Chem; 2007 Sep; 282(36):25993-6001. PubMed ID: 17616532
[TBL] [Abstract][Full Text] [Related]
2. Essential in vivo roles of the C-type lectin receptor CLEC-2: embryonic/neonatal lethality of CLEC-2-deficient mice by blood/lymphatic misconnections and impaired thrombus formation of CLEC-2-deficient platelets.
Suzuki-Inoue K; Inoue O; Ding G; Nishimura S; Hokamura K; Eto K; Kashiwagi H; Tomiyama Y; Yatomi Y; Umemura K; Shin Y; Hirashima M; Ozaki Y
J Biol Chem; 2010 Aug; 285(32):24494-507. PubMed ID: 20525685
[TBL] [Abstract][Full Text] [Related]
3. Functional characterization of recombinant snake venom rhodocytin: rhodocytin mutant blocks CLEC-2/podoplanin-dependent platelet aggregation and lung metastasis.
Sasaki T; Shirai T; Tsukiji N; Otake S; Tamura S; Ichikawa J; Osada M; Satoh K; Ozaki Y; Suzuki-Inoue K
J Thromb Haemost; 2018 May; 16(5):960-972. PubMed ID: 29488681
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effects of polypeptides derived from a snake venom C-type lectin, aggretin, on tumor cell-induced platelet aggregation.
Chang CH; Chung CH; Hsu CC; Peng HC; Huang TF
J Thromb Haemost; 2014 Apr; 12(4):540-9. PubMed ID: 24479713
[TBL] [Abstract][Full Text] [Related]
5. Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2.
Kato Y; Kaneko MK; Kunita A; Ito H; Kameyama A; Ogasawara S; Matsuura N; Hasegawa Y; Suzuki-Inoue K; Inoue O; Ozaki Y; Narimatsu H
Cancer Sci; 2008 Jan; 99(1):54-61. PubMed ID: 17944973
[TBL] [Abstract][Full Text] [Related]
6. A platform of C-type lectin-like receptor CLEC-2 for binding O-glycosylated podoplanin and nonglycosylated rhodocytin.
Nagae M; Morita-Matsumoto K; Kato M; Kaneko MK; Kato Y; Yamaguchi Y
Structure; 2014 Dec; 22(12):1711-1721. PubMed ID: 25458834
[TBL] [Abstract][Full Text] [Related]
7. Essential in vivo roles of the platelet activation receptor CLEC-2 in tumour metastasis, lymphangiogenesis and thrombus formation.
Suzuki-Inoue K
J Biochem; 2011 Aug; 150(2):127-32. PubMed ID: 21693546
[TBL] [Abstract][Full Text] [Related]
8. Platelet adhesion to podoplanin under flow is mediated by the receptor CLEC-2 and stabilised by Src/Syk-dependent platelet signalling.
Navarro-Núñez L; Pollitt AY; Lowe K; Latif A; Nash GB; Watson SP
Thromb Haemost; 2015 May; 113(5):1109-20. PubMed ID: 25694214
[TBL] [Abstract][Full Text] [Related]
9. Physiologic and pathophysiologic roles of interaction between C-type lectin-like receptor 2 and podoplanin: partners from in utero to adulthood.
Suzuki-Inoue K; Osada M; Ozaki Y
J Thromb Haemost; 2017 Feb; 15(2):219-229. PubMed ID: 27960039
[TBL] [Abstract][Full Text] [Related]
10. G
Badolia R; Inamdar V; Manne BK; Dangelmaier C; Eble JA; Kunapuli SP
J Biol Chem; 2017 Sep; 292(35):14516-14531. PubMed ID: 28705934
[TBL] [Abstract][Full Text] [Related]
11. Syk and Src family kinases regulate C-type lectin receptor 2 (CLEC-2)-mediated clustering of podoplanin and platelet adhesion to lymphatic endothelial cells.
Pollitt AY; Poulter NS; Gitz E; Navarro-Nuñez L; Wang YJ; Hughes CE; Thomas SG; Nieswandt B; Douglas MR; Owen DM; Jackson DG; Dustin ML; Watson SP
J Biol Chem; 2014 Dec; 289(52):35695-710. PubMed ID: 25368330
[TBL] [Abstract][Full Text] [Related]
12. [Identification of the novel platelet activation receptor CLEC-2 and Its pathological and physiological roles].
Suzuki Inoue K; Inoue O; Ozaki Y
Rinsho Byori; 2010 Dec; 58(12):1193-202. PubMed ID: 21348239
[TBL] [Abstract][Full Text] [Related]
13. Platelets and cancer-associated thrombosis: focusing on the platelet activation receptor CLEC-2 and podoplanin.
Suzuki-Inoue K
Blood; 2019 Nov; 134(22):1912-1918. PubMed ID: 31778548
[TBL] [Abstract][Full Text] [Related]
14. Platelets promote tumor growth and metastasis via direct interaction between Aggrus/podoplanin and CLEC-2.
Takagi S; Sato S; Oh-hara T; Takami M; Koike S; Mishima Y; Hatake K; Fujita N
PLoS One; 2013; 8(8):e73609. PubMed ID: 23991201
[TBL] [Abstract][Full Text] [Related]
15. A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2.
Suzuki-Inoue K; Fuller GL; García A; Eble JA; Pöhlmann S; Inoue O; Gartner TK; Hughan SC; Pearce AC; Laing GD; Theakston RD; Schweighoffer E; Zitzmann N; Morita T; Tybulewicz VL; Ozaki Y; Watson SP
Blood; 2006 Jan; 107(2):542-9. PubMed ID: 16174766
[TBL] [Abstract][Full Text] [Related]
16. CLEC-2-dependent activation of mouse platelets is weakly inhibited by cAMP but not by cGMP.
Borgognone A; Navarro-Núñez L; Correia JN; Pollitt AY; Thomas SG; Eble JA; Pulcinelli FM; Madhani M; Watson SP
J Thromb Haemost; 2014 Apr; 12(4):550-9. PubMed ID: 24460629
[TBL] [Abstract][Full Text] [Related]
17. Vascular Smooth Muscle Cells Stimulate Platelets and Facilitate Thrombus Formation through Platelet CLEC-2: Implications in Atherothrombosis.
Inoue O; Hokamura K; Shirai T; Osada M; Tsukiji N; Hatakeyama K; Umemura K; Asada Y; Suzuki-Inoue K; Ozaki Y
PLoS One; 2015; 10(9):e0139357. PubMed ID: 26418160
[TBL] [Abstract][Full Text] [Related]
18. Characterization of anti-podoplanin monoclonal antibodies: critical epitopes for neutralizing the interaction between podoplanin and CLEC-2.
Ogasawara S; Kaneko MK; Price JE; Kato Y
Hybridoma (Larchmt); 2008 Aug; 27(4):259-67. PubMed ID: 18707544
[TBL] [Abstract][Full Text] [Related]
19. Novel platelet activation receptor CLEC-2: from discovery to prospects.
Suzuki-Inoue K; Inoue O; Ozaki Y
J Thromb Haemost; 2011 Jul; 9 Suppl 1():44-55. PubMed ID: 21781241
[TBL] [Abstract][Full Text] [Related]
20. Platelets and cancer-associated thrombosis: focusing on the platelet activation receptor CLEC-2 and podoplanin.
Suzuki-Inoue K
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):175-181. PubMed ID: 31808911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
